Biowaiver monographs for immediate-release solid oral dosage forms: Primaquine phosphate

Journal of Pharmaceutical Sciences

Volumn 101, Issue 3, 2012, Pages 936-945

  Nair, Anita ^a   Abrahamsson, Bertil ^b   Barends, Dirk M ^c   Groot, D W ^c   Kopp, Sabine ^d   Polli, James E ^e   Shah, Vinod P ^f   Dressman, Jennifer B ^a  

^a GOETHE UNIVERSITY   (Germany)

^b ASTRAZENECA R AND D   (Sweden)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^f International Pharmaceutical Federation FIP   (Netherlands)

Author keywords

Absorption; Bioavailability; Bioequivalence; Biopharmaceutics Classification System (BCS); Permeability; Primaquine phosphate; Solubility

Indexed keywords

CHLOROQUINE; CLINDAMYCIN; MANNITOL; METOPROLOL; PLACEBO; PRIMAQUINE;

ABDOMINAL PAIN; AREA UNDER THE CURVE; BIOEQUIVALENCE; BOOK; DEPRESSION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERANCE; EPIGASTRIC DISCOMFORT; ETHNIC DIFFERENCE; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYTIC ANEMIA; HUMAN; IN VIVO STUDY; INFECTION; INTRAVASCULAR HEMOLYSIS; MAXIMUM PLASMA CONCENTRATION; METHEMOGLOBINEMIA; NAUSEA AND VOMITING; NEUTROPENIA; NOTE; ORAL DRUG ADMINISTRATION; PH; PKA; PLASMA CLEARANCE; PLASMODIUM OVALE MALARIA; PLASMODIUM VIVAX MALARIA; PNEUMOCYSTIS PNEUMONIA; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SEX DIFFERENCE; SINGLE DRUG DOSE; SOLID; TISSUE DISTRIBUTION;

EID: 84855893015     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23006     Document Type: Note

References (79)

1. Vogelpoel H, Welink J, Amidon GL, Junginger HE, Midha KK, Moller H, Olling M, Shah VP, Barends DM. 2004. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci 93(8):1945-1956.
2. World Health Organization (WHO). 2006. Proposal to waive in vivo bioequivalence requirements for WHO model list of essential medicines immediate-release, solid oral dosage forms. Accessed June 16, 2010, at.
3. U.S. Department of Health and Human Services: Food and Drug Administration. 2000. Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Accessed December 20, 2010, at.
4. European Medicines Agency. 2010. Guideline on the investigation of bioequivalence. Accessed December 20, 2010 at.
5. Chuasuwan B, Binjesoh V, Polli JE, Zhang H, Amidon GL, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2009. Biowaiver monographs for immediate release solid oral dosage forms: Diclofenac sodium and diclofenac potassium. J Pharm Sci 98(4):1206-1219.
6. Grube S, Langguth P, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2009. Biowaiver monographs for immediate release solid oral dosage forms: Quinidine sulfate. J Pharm Sci 98(7):2238-2251.
7. Kalantzi L, Reppas C, Dressman JB, Amidon GL, Junginger HE, Midha KK, Shah VP, Stavchansky SA, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Acetaminophen (paracetamol). J Pharm Sci 95(1):4-14.
8. Granero GE, Longhi MR, Becker C, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Acetazolamide. J Pharm Sci 97(9):3691-3699.
9. Granero GE, Longhi MR, Mora MJ, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2010. Biowaiver monographs for immediate release solid oral dosage forms: Furosemide. J Pharm Sci 99(6):2544-2556.
10. Arnal J, Gonzalez-Alvarez I, Bermejo M, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Aciclovir. J Pharm Sci 97(12):5061-5073.
11. Manzo RH, Olivera ME, Amidon GL, Shah VP, Dressman JB, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Amitriptyline hydrochloride. J Pharm Sci 95(5):966-973.
12. Verbeeck RK, Junginger HE, Midha KK, Shah VP, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride. J Pharm Sci 94(7):1389-1395.
13. Jantratid E, Prakongpan S, Dressman JB, Amidon GL, Junginger HE, Midha KK, Barends DM. 2006. Biowaiver monographs for immediate release solid oral dosage forms: Cimetidine. J Pharm Sci 95(5):974-984.
14. Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Pyrazinamide. J Pharm Sci 97(9):3709-3720.
15. Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Ethambutol dihydrochloride. J Pharm Sci 97(4):1350-1360.
16. Becker C, Dressman JB, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2009. Biowaiver monographs for immediate release solid oral dosage forms: Rifampicin. J Pharm Sci 98(7):2252-2267.
17. Potthast H, Dressman JB, Junginger HE, Midha KK, Oeser H, Shah VP, Vogelpoel H, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms: Ibuprofen. J Pharm Sci 94(10):2121-2131.
18. Stosik AG, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: Metoclopramide hydrochloride. J Pharm Sci 97(9):3700-3708.
19. Kortejarvi H, Yliperttula M, Dressman JB, Junginger HE, Midha KK, Shah VP, Barends DM. 2005. Biowaiver monographs for immediate release solid oral dosage forms: Ranitidine hydrochloride. J Pharm Sci 94(8):1617-1625.
20. Vogt M, Derendorf H, Kramer J, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Prednisone. J Pharm Sci 96(6):1480-1489.
21. Vogt M, Derendorf H, Kramer J, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Prednisolone. J Pharm Sci 96(1):27-37.
22. Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2007. Biowaiver monographs for immediate release solid oral dosage forms: Isoniazid. J Pharm Sci 96(3):522-531.
23. Jantratid E, Strauch S, Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. 2010. Biowaiver monographs for immediate release solid oral dosage forms: Doxycycline hyclate. J Pharm Sci 99(4):1639-1653.
24. Strauch S, Jantratid E, Dressman JB, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. Biowaiver monographs for immediate release solid oral dosage forms: Mefloquine hydrochloride. J Pharm Sci 100(1):11-21.
25. Olivera ME, Manzo RH, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2010. Biowaiver monographs for immediate release solid oral dosage forms: Ciprofloxacin hydrochloride. J Pharm Sci 100(1):22-33.
26. Sweetman SC. edt 2005. Martindale: The complete drug reference. Pharmaceutical Press; London 34th ed.
27. United States Pharmacopoeia. The National Formulary. 2010. (USP 33/NF 28) ed. Rockville, Maryland: The United States Pharmacopoeial Convention Inc.
28. World Health Organization. 2008. The International Pharmacopoeia. 4th ed. (including first supplement). Accessed December 20, 2010 at.
29. The European Pharmacopoeia (Ph. EUR.). 5th ed. 2005. Strasbourg, France: European Directorate for the Quality of Medicines, Council of Europe.
30. Moffat AC, Osselton MD, Widdop B. 2004. Clarke's analysis of drugs and poisons. 3rd ed. New York: Pharmaceutical Press.
31. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. 2006. Primaquine: Report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 75(3):402-415.
32. World Health Organization. 2010. WHO model list of essential medicines. Accessed June 16, 2010, at.
33. Smego RA Jr, Nagar S, Maloba B, Popara M. 2001. A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. Arch Intern Med 161(12):1529-1533.
34. Queener SF. 1995. New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii. J Med Chem 38(24):4739-4759.
35. U.S. Department of Health and Human Services: Food and Drug Administration. 2009. Maximum recommended therapeutic dose (MRTD) database. Accessed December 20, 2010 at:.
36. Center of disease control and prevention. 2009. Guidelines for treatment of malaria in the United States. Accessed September 22, 2010, at.
37. World Health Organization. 2001. The use of antimalarial drugs part II: 1.9 Primaquine. Accessed September 22, 2010 at.
38. World Health Organization. 1995. WHO model prescribing information: Drugs used in parasitic diseases. Accessed June 28, 2010, at.
39. Bottieau E, Van Gompel A, Peetermans WE. 2005. Failure of primaquine therapy for the treatment of Plasmodium ovale malaria. Clin Infect Dis 41(10):1544-1545.
40. Goller JL, Jolley D, Ringwald P, Biggs BA. 2007. Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy. Am J Trop Med Hyg 76(2):203-207.
41. Clyde DF. 1981. Clinical problems associated with the use of primaquine as a tissue schizonticidal and gametocytocidal drug. Bull World Health Org 59(3):391-395.
42. Clayman CB, Arnold J, Hockwald RS, Yount EH Jr, Edgcomb JH, Alving AS. 1952. Toxicity of primaquine in caucasians. J Am Med Assoc 149(17):1563-1568.
43. Baird JK, Hoffman SL. 2004. Primaquine therapy for malaria. Clin Infect Dis 39(9):1336-1345.
44. Schlossberg D. 1980. Reaction to primaquine. Ann Intern Med 92(3):435.
45. Fryauff DJ, Baird JK, Basri H, Sumawinata I, Purnomo, Richie TL, Ohrt CK, Mouzin E, Church CJ, Richards AL, Wignall S, Mouzin E, Ohrt C, Subianto B, Sandjaja B, Hoffman S. 1995. Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet 346(8984):1190-1193.
46. Baird JK, Lacy MD, Basri H, Barcus MJ, Maguire JD, Bangs MJ, Gramzinski R, Sismadi P, Krisin Ling J, Wiady I, Kusumaningsih M, Jones TR, Fryauff DJ, Hoffman SL. 2001. Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis 33(12):1990-1997.
47. U.S. Department of Health and Human Services: Food and Drug Administration. 2010. CFR-Code of Federal Regulation Title 21. Accessed December 20, 2010, at.
48. European directorate for the quality of medicines and healthcare. 2009. Safety data sheet. Accessed September 22, 2010, at.
49. Al-Badr Abdullah A. 2007. Primaquine diphosphate: Comprehensive profile. In Profiles of drug substances, excipients and related methodology; Brittain HG, Ed. New York: Academic Press.
50. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernas H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL. 2004. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 1(1):85-96.
51. Bergstrom CA, Strafford M, Lazorova L, Avdeef A, Luthman K, Artursson P. 2003. Absorption classification of oral drugs based on molecular surface properties. J Med Chem 46(4):558-570.
52. Drug Bank. 2009. Primaquine phosphate. Accessed September 22, 2010, at.
53. Baker KJ. 1983. Assignments of dissociation constants of primaquine by 13C-NMR spectroscopy. J Heterocycl Chem 20:273-275.
54. Stensrud G, Sande SA, Kristensen S, Smistad G. 2000. Formulation and characterisation of primaquine loaded liposomes prepared by a pH gradient using experimental design. Int J Pharm 198(2):213-228.
55. U.S. Department of Health and Human Services: Food and Drug Administration. 2010. Primaquine phosphate. Accessed December 20, 2010 at.
56. Department of Health and Ageing: Therepeutics goods administration A. 2010. Primaquine phosphate. Accessed December 20, 2010 at.
57. CIMS India. 2010. Malirid. Accessed December 20, 2010 at:.
58. Mihaly GW, Ward SA, Edwards G, Orme ML, Breckenridge AM. 1984. Pharmacokinetics of primaquine in man: Identification of the carboxylic acid derivative as a major plasma metabolite. Br J Clin Pharmacol 17(4):441-446.
59. Mihaly GW, Ward SA, Edwards G, Nicholl DD, Orme ML, Breckenridge AM. 1985. Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br J Clin Pharmacol 19(6):745-750.
60. Singhasivanon V, Sabcharoen A, Attanath P, Chongsuphajaisiddhi T, Diquet B, Turk P. 1991. Pharmacokinetics of primaquine in healthy volunteers. Southeast Asian J Trop Med Public Health 22(4):527-533.
61. Fletcher KA, Evans DA, Gilles HM, Greaves J, Bunnag D, Harinasuta T. 1981. Studies on the pharmacokinetics of primaquine. Bull World Health Organ 59(3):407-412.
62. Bhatia SC, Saraph YS, Revankar SN, Doshi KJ, Bharucha ED, Desai ND, Vaidya AB, Subrahmanyam D, Gupta KC, Satoskar RS. 1986. Pharmacokinetics of primaquine in patients with P. vivax malaria. Eur J Clin Pharmacol 31(2):205-210.
63. Ward SA, Mihaly GW, Edwards G, Looareesuwan S, Phillips RE, Chanthavanich P, Warrell DA, Orme ML, Breckenridge AM. 1985. Pharmacokinetics of primaquine in man. II. Comparison of acute vs chronic dosage in Thai subjects. Br J Clin Pharmacol 19(6):751-755.
64. Bangchang KN, Songsaeng W, Thanavibul A, Choroenlarp P, Karbwang J. 1994. Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. Trans R Soc Trop Med Hyg 88(2):220-222.
65. Vale N, Moreira R, Gomes P. 2009. Primaquine revisited six decades after its discovery. Eur J Med Chem 44(3):937-953.
66. Kennedy E, Frischer H. 1990. Distribution of primaquine in human blood: Drug-binding to alpha 1-glycoprotein. J Lab Clin Med 116(6):871-878.
67. Greaves J, Evans DA, Gilles HM, Fletcher KA, Bunnag D, Harinasuta T. 1980. Plasma kinetics and urinary excretion of primaquine in man. Br J Clin Pharmacol 10(4):399-404.
68. Elmes NJ, Bennett SM, Abdalla H, Carthew TL, Edstein MD. 2006. Lack of sex effect on the pharmacokinetics of primaquine. Am J Trop Med Hyg 74(6):951-952.
69. Binh VQ, Chinh NT, Thanh NX, Cuong BT, Quang NN, Dai B, Travers T, Edstein MD. 2009. Sex affects the steady-state pharmacokinetics of primaquine but not doxycycline in healthy subjects. Am J Trop Med Hyg 81(5):747-753.
70. White NJ. 1985. Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet 10(3):187-215.
71. Greaves J, Evans DA, Fletcher KA. 1980. Urinary primaquine excretion and red cell methaemoglobin levels in man following a primaquine:chloroquine regimen. Br J Clin Pharmacol 10(3):293-295.
72. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM. 2003. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 59(5-6):429-442.
73. Kim YR, Kuh HJ, Kim MY, Kim YS, Chung WC, Kim SI, Kang MW. 2004. Pharmacokinetics of primaquine and carboxyprimaquine in Korean patients with vivax malaria. Arch Pharm Res 27(5):576-580.
74. Ronn A, Bygbjerg I. 1993. Unexpected high primaquine concentrations in acutely ill malaria patients. Lancet 341(8840):305.
75. Edwards G, McGrath CS, Ward SA, Supanaranond W, Pukrittayakamee S, Davis TM, White NJ. 1993. Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. Br J Clin Pharmacol 35(2):193-198.
76. Cuong BT, Binh VQ, Dai B, Duy DN, Lovell CM, Rieckmann KH, Edstein MD. 2006. Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects? Br J Clin Pharmacol 61(6):682-689.
77. Lindenberg M, Kopp S, Dressman JB. 2004. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 58(2):265-278.
78. Custodio JM, Wu CY, Benet LZ. 2008. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev 60(6):717-733.
79. Krudsood S, Tangpukdee N, Wilairatana P, Phophak N, Baird JK, Brittenham GM, Looareesuwan S. 2008. High-dose primaquine regimens against relapse of Plasmodium vivax malaria. Am J Trop Med Hyg 78(5):736-740.